Vertex doubles down on diabetes – acquires firm and resumes stem cell study

With the acquisition of Viacyte, a biotech firm focused on stem cell therapies to cure type 1 diabetes, Vertex hopes to accelerate development of its own candidate, which is moving forward following an FDA clinical hold.

US-based Vertex Pharmaceuticals, a biotech firm developing a stem cell-derived candidate for the treatment of type 1 diabetes, is set to acquire a privately owned firm focused on the same area, Viacyte, a company press release reports.

Vertex is not looking to acquire any treatment candidate in particular, instead highlighting how the synergies that the firm acquires for a total price of USD 320m in cash will aid development efforts for the firm’s own candidate, VX-880.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs